| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-074 |
| filingDate |
2003-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56dcafb69582f7bca048c96fdcc1769a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7564fa117c43937a3ddd2e553b3306f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7bea7f6bd222b4621f089d77e13462d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a76e30fdb7b58aab9ff3a2b200d4866e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9234781564e96a22c8726d35883d8f53 |
| publicationDate |
2004-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1488798-A1 |
| titleOfInvention |
HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure |
| abstract |
This invention is based on the experimental finding that HIP/PAPnhas mitogenic and antiapoptotic effects in vitro on hepatocytes in primarynculture. The present invention is also based on the experimental findingnthat HIP/PAP administration has no adverse effects in mammals. Thisninvention concerns a pharmaceutical composition for stimulating livernregeneration in vivo comprising an effective amount of a polypeptidencomprising an amino acid sequence having 90% amino acid identity withnthe polypeptide consisting of the amino acid sequence starting at thenamino acid residue 36 and ending at the amino acid residue 175 ofnsequence SEQ ID N°1, in combination with at least one physiologicallynacceptable excipient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010142800-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8212007-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2590859-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2559935-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9738695-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011229435-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022140457-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9388215-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10899815-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2260857-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2010258565-B2 |
| priorityDate |
2003-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |